# Kura Oncology (KURA) — Analyst Forecast

KURA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/kura/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 15 | 1 | 0 | 16 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $24.00 | $30.67 | $38.00 | 3 |

Last price $9.70 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 1, 2026 | JP Morgan | Initiated Coverage | Overweight | $30.00 |
| Aug 24, 2026 | Citizens | Maintained | Market Outperform | $24.00 |
| Aug 13, 2026 | Wedbush | Maintained | Outperform | $38.00 |
| Jul 28, 2026 | Wedbush | Maintained | Outperform | $36.00 |
| Jun 15, 2026 | Citizens | Maintained | Market Outperform | $24.00 |
| Apr 14, 2026 | Lake Street | Initiated Coverage | Buy | $23.00 |
| Mar 24, 2026 | Mizuho | Maintained | Outperform | $25.00 |
| Mar 13, 2026 | UBS | Maintained | Buy | $15.00 |
| Mar 6, 2026 | Wedbush | Maintained | Outperform | $36.00 |
| Jan 13, 2026 | HC Wainwright & Co. | Maintained | Buy | $40.00 |
| Jan 13, 2026 | Leerink Partners | Maintained | Outperform | $20.00 |
| Nov 24, 2025 | Barclays | Maintained | Overweight | $28.00 |
| Nov 14, 2025 | Wedbush | Maintained | Outperform | $38.00 |
| Nov 14, 2025 | UBS | Maintained | Buy | $16.00 |
| Oct 20, 2025 | HC Wainwright & Co. | Maintained | Buy | $40.00 |
| Oct 20, 2025 | JMP Securities | Maintained | Market Outperform | $24.00 |
| Sep 30, 2025 | HC Wainwright & Co. | Maintained | Buy | $40.00 |
| Sep 4, 2025 | Guggenheim | Initiated Coverage | Neutral | — |
| Aug 11, 2025 | JMP Securities | Maintained | Market Outperform | $24.00 |
| Jun 26, 2025 | Cantor Fitzgerald | Maintained | Overweight | — |

## Frequently Asked Questions

### What is the price target for KURA stock?

The average 12-month analyst price target for Kura Oncology (KURA) is $30.67, with a high estimate of $38.00 and a low of $24.00, across 3 analysts.

### Is KURA a buy, sell, or hold?

Analysts covering Kura Oncology currently average a Buy rating: 15 buy, 1 hold and 0 sell, from 16 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for KURA?

The average price target of $30.67 implies 216.15% upside from the last price of $9.70.

### What is the latest analyst rating on KURA?

On Oct 1, 2026, JP Morgan initiated coverage of Kura Oncology at Overweight with a price target of $30.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).